Objective:

To announce the approval of AMBELVIST (gadoquatrane), a low-dose macrocyclic gadolinium-based contrast agent for MRI.

Approach:

Key Findings:

• AMBELVIST is the lowest-dose macrocyclic gadolinium-based contrast agent approved in the US.
• It delivers 60% less gadolinium than agents containing 0.1 mmol gadolinium/kg body weight.
• Increased lesion visualization was reported with combined precontrast and postcontrast MRI sets.

Interpretation:

Safety and effectiveness in pediatric patients were supported by studies in adults and pharmacokinetic data from 93 pediatric patients.

Limitations:

• AMBELVIST carries a boxed warning regarding risks associated with intrathecal administration and nephrogenic systemic fibrosis.
• It is contraindicated in patients with a history of severe hypersensitivity reactions to AMBELVIST.

Conclusion:

AMBELVIST provides an additional option for contrast-enhanced imaging while reducing gadolinium exposure.

Sources:

• Bayer
Source

Based on findings from:

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

Kathryn Wighton. MDSpire News, 2026.

https://news.mdspire.com/radiology/articles/fda-approves-lowdose-macrocyclic-contrast-agent-for-mri/

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.